Novartis | NOVN - العاصمة قرض





العاصمة قرض تغيير تاريخ
AbbVie USD 58.94B 4.03B 2025-12
Alcon AG USD 4.16B 434M 2026-03
Almirall EUR 324.81M 61.32M 2025-12
Amgen USD 51.89B 1.88B 2026-03
AstraZeneca USD 25.96B 177M 2026-03
Autolus Therapeutics Ltd USD 277.27M 7.07M 2026-03
Bayer EUR 30.68B 1.15B 2026-03
Biogen USD 6.29B 1.7M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Eli Lilly USD 39.37B 1.5B 2026-03
Fresenius EUR 9.22B 1.58B 2025-12
Fresenius Medical Care EUR 5.74B 895.27M 2026-03
Genmab DKK 5.14B 5.01B 2025-12
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 14.01B 696M 2026-03
GRIFOLS EUR 9.08B 612M 2026-03
Hikma Pharmaceutical USD 1.49B 692M 2025-12
J&J USD 37.34B 183M 2026-06
Lakefront Biotherapeutics EUR 4.85M 335K 2026-03
Lonza CHF 3.88B 323M 2025-12
Merck EUR 10.8B 72M 2026-03
Merck USD 46.67B 77M 2026-03
Novartis USD 37.45B 7.86B 2026-03
Novartis USD 37.45B 7.86B 2026-03
Novo Nordisk DKK 119.17B 231M 2026-03
Orion EUR 103.4M 7.2M 2026-06
Pfizer USD 60.57B 1.08B 2026-03
Philips EUR 6.89B 43M 2026-03
Recordati EUR 1.76B 373.2M 2026-03
Regeneron Pharmaceuticals USD 1.99B 719.7M 2026-03
Roche Holding CHF 27.43B 966M 2025-12
Sanofi EUR 13.84B 1.88B 2026-03
UCB EUR 2.18B 634M 2025-12